Trial Profile
GAZYVA, Special Drug Use Surveillance -Patients with CD20-positive follicular lymphoma-
Status:
Recruiting
Phase of Trial:
Phase IV
Latest Information Update: 08 Jan 2022
Price :
$35
*
At a glance
- Drugs Bendamustine (Primary) ; Obinutuzumab (Primary)
- Indications Follicular lymphoma
- Focus Adverse reactions
- Sponsors Chugai Pharmaceutical
- 26 Oct 2018 New trial record
- 23 Oct 2018 Status changed from not yet recruiting to recruiting.